Focus: Investors seek answers on Novo Nordisk's next-gen obesity drug CagriSema
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
Novo Nordisk Foundation Will Not Fill Funding Gaps
Novo’s record profit from obesity drugs has given the Foundation a war chest to fund its philanthropic grants, although ...
No plan to prop up global health, Novo Nordisk Foundation says, as Trump freezes US aid
The Novo Nordisk Foundation does not plan to step in to prop up a global health sector reeling from a freeze on U.S.-funded ...
Novo Nordisk A/S Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - NVO
NEW YORK, NY / ACCESS Newswire / February 3, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about ...
Novo Nordisk A/S Is Being Sued For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESS Newswire / February 3, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a ...
Investors seek answers on Novo Nordisk's next-gen obesity drug CagriSema
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
Jim Cramer Expects Novo Nordisk A/S (NVO) To Forecast A Good 2025
We recently published an article titled Jim Cramer’s Game Plan: 15 Stocks in Focus. In this article, we are going to take a ...